Please login to the form below

Not currently logged in
Email:
Password:

IMI

This page shows the latest IMI news and features for those working in and with pharma, biotech and healthcare.

Is competition the enemy of progress and collaboration the ally of success?

Is competition the enemy of progress and collaboration the ally of success?

Looking to Europe, the Innovative Medicines Initiative (IMI) has brought together more than 70 industry companies with other public and private partners to help researchers tackle some of the EU’s

Latest news

More from news
Approximately 14 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    EPAD is co-funded by the Innovative Medicines Initiative (IMI) and Europe’s pharma industry organisation EFPIA, and 2019 will see the first patients being treated by this groundbreaking new alliance. ... Funding for EPAD from IMI comes to an end in

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    She made major scientific contributions to neuroscience R&D within the pharmaceutical industry at GlaxoSmithkline, and also championed the vision for the Stevenage Bioscience Catalyst and theEuropean Innovative Medicines Initiative (IMI).

  • A quest for innovative solutions A quest for innovative solutions

    The innovative Medicines Initiative (IMI), with 5.3bn invested in 90 projects, is a barometer of the industry’s deep dive into technology at a time when ageing populations with multiple

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    There are a number of collaborations we have with biotech companies in Europe, but regarding the IMI collaboration, it is too early yet for discussion.”. ... Several other companies are signed up to the IMI's efforts in AMR, including GlaxoSmithKline,

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    of working with local academics, while the Innovative Medicines Initiative (IMI) is bringing EFPIA members together with academics and biotechs to research major public health problems.

More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Innovative Medicines Initiative appoints executive director Innovative Medicines Initiative appoints executive director

    Pierre Meulien joins from Genome Canada . Innovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September. ... Pierre Meulien's invaluable experience will help IMI deliver on its ambitious objectives.”.

  • IMI picks Ipsen's Marc de Garidel to chair governing board IMI picks Ipsen's Marc de Garidel to chair governing board

    Its second-phase IMI 2 programme aims to develop next generation vaccines, medicines and treatments, such as new antibiotics. ... I am confident that his decades of experience working in the pharmaceutical sector will prove invaluable to IMI.”.

  • IMI appoints new chair of scientific committee IMI appoints new chair of scientific committee

    Prof Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI). ... Finally, there is huge potential to expand the principles underlying IMI to the rest of the world.”.

  • Hans Lennernas joins board of CMO Recipharm Hans Lennernas joins board of CMO Recipharm

    Prof Lennernäs is currently a professor of biopharmaceuticals at Uppsala University in Sweden, where he manages an Innovative Medicines Initiative (IMI) project called OrBiTo, which aims to improve the delivery of

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy
OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy...
Cannes or Canned
Creating a culture where innovation thrives
It starts with us...
David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...

Infographics